Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).
Risankizumab had greater improvements in skin clearance and quality of life at 16 weeks in patients with psoriasis compared with deucravacitinib.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback